Leo Wealth LLC Sells 16,394 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)

Leo Wealth LLC reduced its stake in Gilead Sciences, Inc. (NASDAQ:GILD) by 58.3% in the fourth quarter, HoldingsChannel reports. The institutional investor owned 11,705 shares of the biopharmaceutical company’s stock after selling 16,394 shares during the quarter. Leo Wealth LLC’s holdings in Gilead Sciences were worth $1,081,000 as of its most recent SEC filing.

Several other large investors have also bought and sold shares of the stock. GHP Investment Advisors Inc. raised its holdings in shares of Gilead Sciences by 1.1% in the fourth quarter. GHP Investment Advisors Inc. now owns 11,354 shares of the biopharmaceutical company’s stock valued at $1,049,000 after purchasing an additional 122 shares during the last quarter. Beacon Financial Advisory LLC bought a new stake in Gilead Sciences in the 4th quarter worth about $206,000. Adero Partners LLC purchased a new stake in Gilead Sciences in the 4th quarter valued at about $230,000. YANKCOM Partnership purchased a new position in shares of Gilead Sciences in the 4th quarter worth approximately $28,000. Finally, Bleakley Financial Group LLC grew its holdings in shares of Gilead Sciences by 10.5% in the fourth quarter. Bleakley Financial Group LLC now owns 25,484 shares of the biopharmaceutical company’s stock valued at $2,354,000 after acquiring an additional 2,414 shares in the last quarter. 83.67% of the stock is currently owned by institutional investors.

Gilead Sciences Stock Down 1.6 %

Shares of NASDAQ:GILD opened at $98.04 on Friday. The company has a market cap of $122.18 billion, a price-to-earnings ratio of 1,089.33, a PEG ratio of 1.37 and a beta of 0.18. Gilead Sciences, Inc. has a one year low of $62.07 and a one year high of $100.51. The firm has a fifty day moving average price of $92.86 and a two-hundred day moving average price of $86.41. The company has a debt-to-equity ratio of 1.24, a current ratio of 1.26 and a quick ratio of 1.10.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings data on Wednesday, November 6th. The biopharmaceutical company reported $2.02 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.58 by $0.44. The company had revenue of $7.55 billion during the quarter, compared to analyst estimates of $7.01 billion. Gilead Sciences had a return on equity of 29.00% and a net margin of 0.45%. The firm’s quarterly revenue was up 7.0% on a year-over-year basis. During the same quarter last year, the company earned $2.29 earnings per share. Analysts anticipate that Gilead Sciences, Inc. will post 4.34 EPS for the current fiscal year.

Insider Activity

In related news, insider Merdad Parsey sold 164,211 shares of the firm’s stock in a transaction dated Wednesday, November 27th. The stock was sold at an average price of $91.92, for a total transaction of $15,094,275.12. Following the transaction, the insider now directly owns 80,801 shares of the company’s stock, valued at approximately $7,427,227.92. This trade represents a 67.02 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, CFO Andrew D. Dickinson sold 248,645 shares of the business’s stock in a transaction dated Friday, November 29th. The shares were sold at an average price of $92.76, for a total value of $23,064,310.20. Following the completion of the sale, the chief financial officer now directly owns 138,919 shares of the company’s stock, valued at approximately $12,886,126.44. This trade represents a 64.16 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 572,824 shares of company stock worth $53,611,715. 0.29% of the stock is currently owned by insiders.

Analyst Ratings Changes

A number of analysts recently commented on the company. Mizuho lifted their price target on Gilead Sciences from $90.00 to $100.00 and gave the stock an “outperform” rating in a report on Thursday, November 21st. The Goldman Sachs Group lifted their target price on Gilead Sciences from $74.00 to $84.00 and gave the stock a “neutral” rating in a research note on Thursday, November 7th. Sanford C. Bernstein assumed coverage on shares of Gilead Sciences in a research report on Thursday, October 17th. They set an “outperform” rating and a $105.00 price target for the company. Bank of America reaffirmed a “buy” rating and issued a $109.00 price objective on shares of Gilead Sciences in a research report on Tuesday, December 10th. Finally, Maxim Group downgraded shares of Gilead Sciences from a “buy” rating to a “hold” rating in a research report on Friday, November 8th. Eleven equities research analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and four have assigned a strong buy rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $98.39.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.